Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- rilonacept
- Simponi (golimumab)
Interactions between your drugs
rilonacept golimumab
Applies to: rilonacept, Simponi (golimumab)
GENERALLY AVOID: The use of an interleukin-1 (IL-1) blocker in combination with a tumor necrosis factor (TNF) blocker may increase the risk of neutropenia and serious infections, possibly due to additive immunosuppressive effects. In a clinical study, neutropenia occurred in 3% and serious infections in 7% of patients receiving the IL-1 blocker anakinra in combination with a TNF blocker (n=58). No added benefit has been observed with the combination relative to either agent alone.
MANAGEMENT: Concomitant use of an IL-1 blocker and a TNF blocker is not recommended.
References (8)
- (2001) "Product Information. Kineret (anakinra)." Amgen
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Pharmaceutical Society of Australia (2006) APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp
- Cerner Multum, Inc. "Australian Product Information."
- (2008) "Product Information. Cimzia (certolizumab)." UCB Pharma Inc
- (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc
- (2009) "Product Information. Simponi (golimumab)." Centocor Inc
- (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Arcalyst
Arcalyst (rilonacept) is used to treat Cryopyrin-Associated Periodic Syndromes, Deficiency of ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Bimzelx
Bimzelx (bimekizumab) treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and ...
Cinqair
Cinqair (reslizumab) is a monoclonal antibody that affects the actions of the body's immune system ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Ebglyss
Ebglyss (lebrikizumab) is a treatment for moderate-to-severe atopic dermatitis given as a monthly ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.